Draft Guidance on Regorafenib
March 2021

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

This guidance, which interprets the Agency’s regulations on bioequivalence at 21 CFR part 320, provides product-specific recommendations on, among other things, the design of bioequivalence studies to support abbreviated new drug applications (ANDAs) for the referenced drug product. FDA is publishing this guidance to further facilitate generic drug product availability and to assist the generic pharmaceutical industry with identifying the most appropriate methodology for developing drugs and generating evidence needed to support ANDA approval for generic versions of this product.

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. FDA guidance documents, including this guidance, should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA guidances means that something is suggested or recommended, but not required.

In December 2014, FDA issued a draft product-specific guidance for industry on generic regorafenib. We are now issuing revised draft guidance for industry that replaces the previously issued guidance.

Active Ingredient: Regorafenib
Dosage Form; Route: Tablet; oral
Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 40 mg
   Subjects: Males and females not of reproductive potential, general population
   Additional comments: Screen subjects to ensure normal clinical laboratory tests, including hepatic and renal function, electrocardiogram, and normal range blood pressure. Additionally, instruct males with female partners of reproductive potential to use effective contraception during the study and for 2 months after the final dose.
2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 40 mg
   Subjects: Males and females not of reproductive potential, general population
   Additional comments: See comments above.

Analyte to measure: Regorafenib in plasma

Bioequivalence based on (90% CI): Regorafenib

Waiver request of in vivo testing: Not applicable

Dissolution test method and sampling times: The dissolution information for this drug product can be found in the FDA’s Dissolution Methods database, http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units for each of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application.

Revision History: Recommended December 2014; Revised March 2021

Unique Agency Identifier: PSG_203085